PolyNovo (ASX:PNV) said its NovoSorb BTM and NovoSorb MTX devices available for sale in the US are only subject to the 10% tariff imposed on exports to the US and will not be affected by the new tariffs on pharmaceutical products, according to a Tuesday filing with the Australian bourse.
The medical technology firm also said it has about a year's worth of inventory within the US, with the capacity to increase levels.